Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

benzinga.com/general/biotech/25/05/45410642/exelixis-crushes-q1-earnings-estimates-with-strong-cabometyx-sales-raises-2025-revenue-guidance

Exelixis Inc. (NASDAQ:EXEL) reported adjusted earnings of 62 cents per share on Tuesday for the first quarter of 2025, compared to 17 cents a year ago, beating the consensus of 36 cents.
The cancer-focused company reported quarterly sales of $555.45 million, beating the consensus of…

This story appeared on benzinga.com, 2025-05-14 14:44:27.
The Entire Business World on a Single Page. Free to Use →